Answers are grounded in this paper and cite their sources.
Glioblastoma (GBM) is an aggressive primary malignant brain tumor that infiltrates normal brain parenchyma along white matter tracts and perivascular spaces (contact guidance) without distinct anatomical borders, leading to frequent local recurrence near the resection margin. Moreover, anatomical constraints and recurrence pathways differ substantially between superficial cortical lesions (frontal, temporal, and parietal lobes) and deep-seated lesions (thalamus, basal ganglia, and periventricular regions). This paper proposes a location-adaptive, four-stage hybrid therapeutic platform designed for minimally invasive spatial control of GBM across any intracranial location, guided by preoperative diffusion tensor imaging (DTI) tractography. The protocol comprises: (1) MRI-monitored core cytoreduction (partial cryoablation or laser interstitial thermal therapy [LITT]) paired with slow fractional drainage; (2) 5-aminolevulinic acid (5-ALA) blue-light fiber-optic endoscopic margin verification and directional anti-adhesion barrier coating (Push) over eloquent neural tracts; (3) location-adaptive CXCL12 chemotactic motility trapping (Pull) via either an aligned polycaprolactone (PCL) nanofiber conduit leading to a subcutaneous extracortical trap (Mode A: superficial lesions) or a periventricular thermosensitive hydrogel trap coupled to an Ommaya reservoir (Mode B: deep-seated lesions), enabling safe physical extraction or replacement without injuring healthy brain tissue; and (4) 200 kHz deep cross-fire tumor-treating fields (TTFields), 5-ALA sonodynamic therapy (SDT), and trap-harvested neoantigen-based immunotherapy (CAR-T / mRNA vaccines). To bridge the gap before next-generation biomaterials receive full regulatory approval, a near-term clinical translation roadmap utilizing currently approved medical devices and drugs—alongside a modular working-sheath catheter architecture designed to lower regulatory barriers—is also presented.
No takes yet. Share an insight, caveat, or question.
Youngbae Lee (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: